Huang Shenshen, Qiu Jiayong, Wang Anyi, Ma Yuejiao, Wang Peiwen, Ding Dong, Qiu Luhong, Li Shuangping, Liu Mengyi, Zhang Jiexin, Mao Yimin, Yan Yi, Xu Xiqi, Jing Zhicheng
Department of Respiratory and Critical Care Medicine, The First Affiliated Hospital, and College of Clinical Medicine of Henan University of Science and Technology, Luoyang, Henan 471003, China.
Department of Respiratory and Critical Care Medicine, The Second Hospital of Hebei Medical University, Shijiazhuang, Hebei 050000, China.
Chin Med J (Engl). 2025 Jun 5;138(11):1324-1333. doi: 10.1097/CM9.0000000000003559. Epub 2025 May 16.
Pulmonary arterial hypertension (PAH) presents a significant health burden in Asia and remains a critical challenge. This study aims to delineate the PAH burden in Asia from 1990 to 2021.
Using the latest data from the Global Burden of Disease 2021, we evaluated and analyzed the distributions and patterns of PAH disease burden among various age groups, sexes, regions, and countries in Asia. Additionally, we examined the associations between PAH disease burden and key health system indicators, including the socio-demographic index (SDI) and the universal health coverage (UHC) index.
In 2021, there were 25,989 new PAH cases, 103,382 existing cases, 13,909 PAH-associated deaths, and 385,755 DALYs attributed to PAH in Asia, which accounted for approximately 60% of global PAH cases. The age-standardized rates (ASRs) for prevalence and deaths were 2.05 (95% uncertainty interval [UI]: 1.66-2.52) per 100,000 population and 0.31 (95% UI: 0.23-0.38) per 100,000 population, respectively. From 1990 to 2021, Asia reported the lowest ASRs for PAH prevalence but the highest ASRs for deaths compared to other continents. While the ASRs for prevalence increased slightly, ASRs for mortality and DALYs decreased over time. This increasing burden of PAH was primarily driven by population growth and aging. The burden was especially pronounced among individuals aged ≥60 years and <9 years, who collectively accounted for the majority of deaths and DALYs. Moreover, higher SDI and UHC levels were linked to reduced incidence, but higher prevalence rates.
Although progress has been made in reducing PAH-related mortality and DALYs, the disease continues to impose a substantial burden in Asia, particularly among older adults and young children. Region-specific health policies should focus on improving early diagnosis, expanding access to treatment, and effectively addressing the growing PAH burden in the region.
肺动脉高压(PAH)在亚洲造成了重大的健康负担,仍然是一项严峻挑战。本研究旨在描绘1990年至2021年亚洲的PAH负担情况。
利用《2021年全球疾病负担》的最新数据,我们评估并分析了亚洲不同年龄组、性别、地区和国家中PAH疾病负担的分布及模式。此外,我们还研究了PAH疾病负担与关键卫生系统指标之间的关联,包括社会人口指数(SDI)和全民健康覆盖(UHC)指数。
2021年,亚洲有25989例新的PAH病例、103382例现患病例、13909例PAH相关死亡病例以及PAH所致的385755伤残调整生命年(DALY),约占全球PAH病例的60%。患病率和死亡率的年龄标准化率(ASR)分别为每10万人口2.05(95%不确定区间[UI]:1.66 - 2.52)和每10万人口0.31(95% UI:0.23 - 0.38)。从1990年到2021年,与其他各大洲相比,亚洲报告的PAH患病率ASR最低,但死亡率ASR最高。虽然患病率ASR略有上升,但死亡率和DALY的ASR随时间下降。PAH负担的增加主要是由人口增长和老龄化推动的。这种负担在60岁及以上和9岁以下的人群中尤为明显,他们共同构成了大多数死亡病例和DALY。此外,较高的SDI和UHC水平与发病率降低相关,但患病率较高。
尽管在降低PAH相关死亡率和DALY方面已取得进展,但该疾病在亚洲仍造成巨大负担,尤其是在老年人和幼儿中。针对特定地区的卫生政策应侧重于改善早期诊断、扩大治疗可及性,并有效应对该地区不断增加的PAH负担。